Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Novartis Pharmaceuticals
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05849298CT.gov A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | — | Active Not Recruiting | — | — | — |
NCT06095089CT.gov A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT05150236CT.gov EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | — | Unknown | — | — | — |
NCT05162573CT.gov EBRT + Lu-PSMA for N1M0 Prostate Cancer | — | Completed | — | — | — |
NCT04689828CT.gov 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04720157CT.gov An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | — | Active Not Recruiting | — | — | — |
NCT04430192CT.gov Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | — | Active Not Recruiting | — | — | — |
NCT03828838CT.gov Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vipivotide Tetraxetan (this asset) | Novartis Pharmaceuticals | P3 | BB · 64 |
| Docetaxel | Merck Sharp & Dohme LLC | P4 | BBB |
| Degarelix | Novartis Pharmaceuticals | P4 | BBB |
| Prednisone | Merck Sharp & Dohme LLC | P3 | BBB |
| Leuporelin | Dana-Farber Cancer Institute | P4 | BB |
| Abiraterone | Qilu Pharmaceutical Co., Ltd. | P3 | BB |
| Radium Ra-223 | Bayer | P3 | BB |
| Prednisolone | Eli Lilly and Company | P3 | BB |
| Gozetotide | Telix Pharmaceuticals (Innovations) Pty Limited | P3 | BB |
+42 more in the Prostate Neoplasm cohort
Other indications for Vipivotide Tetraxetan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Adenocarcinoma | — | P3 | BB · 67 |
| Renal Cell Carcinoma | — | P3 | BB · 66 |
| Prostate Carcinoma | — | P2 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vipivotide Tetraxetan in Prostate Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vipivotide-tetraxetan-prostate-neoplasm-116683
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →